Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cue Biopharma (CUE) EBT (2017 - 2025)

Cue Biopharma's EBT history spans 9 years, with the latest figure at -$7.3 million for Q3 2025.

  • For Q3 2025, EBT rose 13.68% year-over-year to -$7.3 million; the TTM value through Sep 2025 reached -$37.2 million, up 14.35%, while the annual FY2024 figure was -$39.9 million, 19.42% up from the prior year.
  • EBT for Q3 2025 was -$7.3 million at Cue Biopharma, up from -$8.4 million in the prior quarter.
  • Across five years, EBT topped out at -$7.3 million in Q3 2025 and bottomed at -$14.3 million in Q1 2022.
  • The 5-year median for EBT is -$12.1 million (2024), against an average of -$11.2 million.
  • The largest annual shift saw EBT plummeted 80.42% in 2022 before it rose 27.72% in 2024.
  • A 5-year view of EBT shows it stood at -$7.9 million in 2021, then tumbled by 80.42% to -$14.2 million in 2022, then increased by 9.18% to -$12.9 million in 2023, then grew by 27.72% to -$9.3 million in 2024, then rose by 21.72% to -$7.3 million in 2025.
  • Per Business Quant, the three most recent readings for CUE's EBT are -$7.3 million (Q3 2025), -$8.4 million (Q2 2025), and -$12.1 million (Q1 2025).